Ghana's pharmaceutical industry charts a new course after COVID
The pandemic exposed uncomfortable truths about Africa's medicine supply chains. When global freight stalled in early 2020, shelves in Accra and Kumasi emptied faster than warehouses in Sydney or Melbourne could have imagined. Ghana, like much of West Africa, imported roughly seventy percent of its finished pharmaceutical products, leaving the country vulnerable to shipping disruptions and export restrictions from India and China.
Since then, a quiet transformation has taken root. Local drugmakers expanded production lines, regulators tightened oversight, and new partnerships formed between Ghanaian firms and international donors. The shift is not about replacing global trade. It is about resilience, ensuring that a cholera outbreak or the next viral emergency does not paralyse patient care.
For Australian readers, the comparison is familiar. The Therapeutic Goods Administration oversees one of the most rigorous medicine approval systems in the world, and the Pharmaceutical Benefits Scheme subsidises essential products nationwide. Ghana's emerging framework borrows some of these principles, adapting them to a different population, budget, and industrial base.
What follows is a closer look at how local manufacturing has evolved, where the gaps remain, and what Australian stakeholders can learn from Ghana's path.
From import dependency to domestic capacity
Before 2020, Ghana hosted around thirty-eight registered local manufacturers, most producing simple generics such as analgesics, antimalarials, and oral rehydration salts. Many facilities operated below international good-manufacturing-practice standards, and raw materials still arrived from abroad.
The pandemic forced a reckoning. Through the Ghana Investment Promotion Centre and the Pharmaceutical Manufacturers Association of Ghana, the government fast-tracked loans and grants for factory upgrades. Firms such as Ernest Chemists, Kinapharma, and Atlantic Life Sciences invested in new packaging lines, sterility testing, and tablet-coating equipment.
The result is a sector that now produces a wider share of the medicines used in public hospitals and community pharmacies. Import substitution has not eliminated overseas suppliers, but it has shifted the conversation from survival to strategy.
Active pharmaceutical ingredients and the supply gap
Manufacturing a finished tablet requires active pharmaceutical ingredients, the chemical compounds that actually treat disease. This remains Ghana's weak link. Local API production is limited to a handful of pilot projects, leaving manufacturers dependent on Chinese and Indian exporters.
Efforts are underway to change this. The Africa Continental Free Trade Area opens the door to a regional API hub, with Ghana positioned as a possible anchor due to its port infrastructure in Tema. Universities such as Kwame Nkrumah University of Science and Technology have launched formulation chemistry programs.
The lesson for Australian observers is straightforward. Shortages of common antibiotics during 2023 reminded Sydney-based pharmacists that global supply chains are fragile everywhere.
Regulation, standards, and export potential
The Food and Drugs Authority in Ghana has tightened its licensing regime, requiring World Health Organization prequalification for products destined for donor-funded tenders. Audits have become more frequent, and counterfeit medicines, once a major concern in West African markets, are now tracked through a national serialisation system.
This regulatory strengthening matters beyond Ghana's borders. Several local firms have begun exporting to neighbouring countries, and a few are pursuing entry into the East African Community market. For Australian importers, the implication is that Ghanaian generics may soon meet quality benchmarks high enough for consideration in regional tenders.
Distribution itself has evolved, with secure track-and-trace systems now standard. Similar principles of controlled access that protect vulnerable users in other industries are being adapted to safeguard medicine supply chains.
Workforce, research, and innovation hubs
A pharmaceutical industry is only as strong as the people running it. Ghana has expanded undergraduate pharmacy programs and introduced new short courses in regulatory affairs, bioprocess engineering, and clinical trial management. Research clusters have formed around the University of Ghana and the Noguchi Memorial Institute for Medical Research.
Innovation hubs in Accra and Kumasi now host small teams working on herbal standardisation, point-of-care diagnostics, and digital prescription tools. Some projects attract funding from diaspora investors in Perth and Brisbane who see opportunity in Africa's expanding middle class.
Australian connections and what they reveal
Australia's pharmaceutical sector offers a useful mirror. Local manufacturing here accounts for a small but vital share of the domestic market, focused on niche products, sterile injectables, and clinical trial supplies. The Pharmaceutical Benefits Scheme keeps medicines affordable, while the TGA ensures safety. Ghana's emerging regulatory architecture echoes that combination of affordability and rigour.
Practical touchpoints continue to grow. Australian companies have supplied packaging machinery to Ghanaian plants, and Australian universities host Ghanaian PhD candidates studying pharmaceutical microbiology. Health partnerships between institutions in Adelaide and Accra are now routine.
Comparing Ghana and Australia side by side
Power reliability remains a problem in some Ghanaian industrial zones, raising production costs. Foreign exchange volatility complicates the purchase of machinery and APIs. Counterfeiting has declined but not vanished, particularly in informal markets along the country's borders. Climate change adds another layer, with heatwaves disrupting cold chains and humidity challenging coastal storage.
How does the Ghanaian system compare with Australia's?
| Aspect | Ghana | Australia |
|---|---|---|
| Share of medicines produced locally | Around 30 percent of finished products | Roughly 15–20 percent, focused on niche products |
| Main regulator | Food and Drugs Authority | Therapeutic Goods Administration |
| Subsidy framework | National Health Insurance Scheme | Pharmaceutical Benefits Scheme |
| Primary export markets | West African neighbours | Asia-Pacific and Pacific Islands |
| Workforce pipeline | Expanding pharmacy and chemistry programs | Specialised clinical research and bioprocess training |
Practical steps for investors and partners
The next five years will likely determine whether Ghana's pharmaceutical industry becomes a regional anchor or remains a work in progress. Capital is flowing, but it needs direction. For Australian stakeholders watching closely, several actions stand out.
- Support joint ventures with Ghanaian API start-ups through development finance institutions.
- Encourage student exchanges between Australian and Ghanaian pharmacy schools.
- Promote regulatory harmonisation between the TGA and the Ghana Food and Drugs Authority.
- Invest in solar-powered cold-chain infrastructure for medicines.
- Expand telehealth pilots that link Brisbane specialists with Ghanaian prescribers.
- Back regional serialisation standards to keep counterfeit products out of circulation.
- Explore reciprocal recognition of good-manufacturing-practice certifications.
Looking ahead together
Ghana's pharmaceutical story is still being written. The country has moved from reactive improvisation during the pandemic toward deliberate industrial policy, and Australian readers will recognise many of the same ambitions, pressures, and trade-offs that shape their own health system. Subscribe to OkayGH.com for weekly updates on African business, health, and culture, and share this piece with anyone tracking the continent's industrial rise.